Oscar Health (OSCR) Cash & Equivalents (2020 - 2026)

Oscar Health has reported Cash & Equivalents for 7 years, with the latest figure at $4.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 114.85% year-over-year to $4.8 billion; the trailing twelve-month figure through Mar 2026 stood at $4.8 billion (up 114.85% YoY), and the FY2025 full-year result was $2.8 billion, up 81.65% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.8 billion, up from $2.8 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $4.8 billion in Q1 2026, with the low at $1.2 billion in Q3 2024.
• Historically, Cash & Equivalents has averaged $2.2 billion across 5 years, with a median of $2.1 billion in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 33.75% — and 2026, when it jumped 114.85%.
• Oscar Health's Cash & Equivalents stood at $1.6 billion in 2022, then climbed by 20.0% to $1.9 billion in 2023, then fell by 18.35% to $1.5 billion in 2024, then soared by 81.65% to $2.8 billion in 2025, then surged by 73.21% to $4.8 billion in 2026.
• The last three Cash & Equivalents figures came in at $4.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.